BMS, Eisai Team Up To Accelerate Development Of Solid-Tumor ADC
Executive Summary
The US firm gets development and co-commercial rights to MORAb-202 for $650m up front. BMS joins AstraZeneca, Merck & Co. and Gilead in recent ADC deal-making.
You may also be interested in...
One-Offs Boost Japan's Top Firms In Mixed Q1
Japan's top pharma firms benefited in several cases from one-off factors in what was a generally positive fiscal first quarter, but most full-year guidance remains unchanged for now.
BMS Sighs In Relief As Opdivo Returns To Sales Growth
With full-year 2020 and Q1 sales down due to pandemic, the company celebrates the PD-1 therapy’s growth in Q2. CAR-T products Breyanzi, Abecma are off to solid launches but face manufacturing hurdles.
Deal Watch: Roche Terminates Gene Therapy Alliance, Partners In IBD With Synlogic
Roche gives back choroideremia candidate to 4D Molecular after reviewing Phase I data, partners on synthetic GI therapy with Synlogic. AbbVie opts to acquire TeneoOne under 2019 agreement.